Posted by Michael Wonder on 02 Apr 2021
AbbVie announces extension of review for supplemental new drug application of upadacitinib for the treatment of moderate to severe atopic dermatitis
2 April 2021 - AbbVie announced that the U.S. FDA has extended the review period for the supplemental new drug application for upadacitinib in the treatment of adults and adolescents with moderate to severe atopic dermatitis.
The Prescription Drug User Fee Act action date has been extended three months to early Q3 2021.
